Strontium Ranelate Production Cost Reports

The report provides a detailed analysis essential for establishing a strontium ranelate production plant. It encompasses all critical aspects necessary for strontium ranelate production, including the cost of strontium ranelate production, strontium ranelate plant cost, strontium ranelate production costs, and the overall strontium ranelate production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a strontium ranelate production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Strontium ranelate is a medicinal compound mainly used in the treatment of osteoporosis, which is a condition that weakens bones and increases the risk of fractures. It is primarily prescribed as a medication to help improve bone strength by supporting new bone formation and reducing bone breakdown. It is mainly used as an oral drug in postmenopausal women and older adults who are at high risk of bone fractures. It works by supporting bone formation while also slowing down bone breakdown, which helps improve bone strength and density. It is also used as a component in the production of oral tablets used in long-term osteoporosis management. It plays an important role in improving bone health and lowering the chances of spine and hip fractures in individuals with weak bones. In addition, it is also studied for its potential benefits in improving bone mineral density and overall bone health.

The primary factor that drives the market for strontium ranelate is its application as an oral medication for the treatment of osteoporosis, which supports its demand in the medical sector. Its application for reducing the risk of bone fractures in postmenopausal women and in certain patients with high fracture risk largely boosts its demand in the pharmaceutical industry. Its usage as a part of long-term treatment plans for managing severe osteoporosis further drives its demand in the medical and healthcare sectors.

Its demand in healthcare and clinical settings as part of treatment plans for patients who cannot tolerate other common osteoporosis medicines also contributes to its market growth. Moreover, advancements in drug production technologies, supplier reliability, compliance with healthcare regulations, and efficient distribution systems largely impact industrial strontium ranelate procurement globally. Several factors, including the cost and availability of raw materials, strict regulatory approvals, clinical safety requirements, and quality standards, also influence its overall market and procurement decisions.

Raw Material for Strontium Ranelate Production

According to the strontium ranelate production plant project report, the major raw materials for strontium ranelate production include Sodium Ranelate and Strontium Chloride.

Production Process of Strontium Ranelate

The extensive strontium ranelate production cost report consists of the following industrial production process:

1. Production via Ion-Exchange Reaction: The production process of strontium ranelate begins with dissolving the sodium salt of ranelic acid in purified water to form a clear solution. Once fully dissolved, an aqueous solution of strontium chloride is slowly added under controlled stirring, which allows a double displacement reaction to take place where strontium ions replace the sodium ions. This leads to the formation of strontium ranelate, which gradually precipitates out of the solution. Then, the solid product is separated by filtration, washed to remove residual sodium chloride and other impurities, and carefully dried to obtain strontium ranelate as the final product.

Strontium ranelate is a strontium(II) salt of ranelic acid and acts as a dual-action bone agent used in the treatment of severe osteoporosis. It appears as a white to light yellow powder or crystalline powder that is odourless. The molecular formula of the compound is C12H6N2O8SSr2, and its molecular mass is 513.49 g/mol. It has a density of approximately 1.8 g/cm³, and it is slightly soluble in water at approximately 1 mg/mL when warmed, but is almost insoluble in ethanol and DMSO. It gets easily dissolved in dilute hydrochloric acid. The compound decomposes at its melting point of approximately 310 degree Celsius. The compound exhibits a unique pharmacological mechanism as it both increases deposition of new bone by osteoblasts while simultaneously reducing bone resorption by osteoclasts. It is classified as moderately toxic if swallowed, and precautions should be taken during handling. It is marketed under the trade name "PROTELOS”. It is generally stored under an inert atmosphere in a freezer at -20 degree Celsius. Extended exposure or improper use may lead to serious health concerns, including increased risk of venous thromboembolism, pulmonary embolism, myocardial infarction, and severe allergic reactions, including DRESS syndrome.